Vascular repair after menstruation involves regulation of vascular endothelial growth factor-receptor phosphorylation by sFLT-1

American Journal of Pathology

Volumn 158, Issue 4, 2001, Pages 1399-1410

  Graubert, Michael D ^a   Ortega, Maria Asuncion ^b   Kessel, Bruce ^a   Mortola, Joseph F ^a   Iruela Arispe, M Luisa ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN RECEPTOR;

ADULT; ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; ENDOMETRIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MENSTRUAL CYCLE; MENSTRUATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; TISSUE REGENERATION;

EID: 0035067625     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64091-6     Document Type: Article

References (55)

1. Angiogenesis in the female reproductive system
2. Angiogenesis in the human female reproductive tract
3. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development
4. Blood vessel growth in the endometrium
5. Growth factors in human endometrium
6. Menstruation in intraocular endometrial transplants in the rhesus monkey
7. Endometrial microstructure: Structure-function relationships throughout the menstrual cycle
8. The repithelialization of endometrium after menstrual desquamation
9. Endothelial cell migratory signal produced by human endometrium during the menstrual cycle
10. Growth factors and cytokines in endometrium, embryonic development, and maternal: Embryonic interactions
11. Identification and localization of alternatively spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines
12. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
13. Vascular endothelial growth factor expression in cycling human endometrium
14. Lack of correlation between vascular endothelial growth factor production and endothelial cell proliferation in the human endometrium
15. No cyclicity in serum vascular endothelial growth factor during normal menstrual cycle but significant luteal phase elevation during an in vitro fertilization program
16. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium
17. Ovarian steroid and cytokine modulation of human endometrial angiogenesis
18. Vascular dysfunction by prolonged activation of progesterone receptor
19. Dating the endometrial biopsy
20. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
21. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium
22. Endometrial endothelia cells express estrogen and progesterone receptors and exhibit a tissue specific response to angiogenic growth factors
23. Oxygen, genes, and development: An analysis of the role of hypoxic gene regulation during murine vascular development
24. Monoclonal antibody Ki-67: Its use in histopathology
25. Analysis of variance
26. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
27. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis
28. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis for endometriosis
29. The isolation and long-term culture of normal human endometrial epithelium and stroma. Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges
30. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells
31. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma
32. Neutrophils infiltrating the endometrium express vascular endothelial growth factor: Potential role in endometrial angiogenesis
33. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
34. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells
35. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
36. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
37. Identification of a human VPF/VEGF 3′ untranslated region mediating hypoxia-induced mRNA stability
38. Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: Potential relevance to menstruation and endometrial regeneration
39. Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia
40. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
41. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells
42. Immunohistochemical localization of transforming growth factor-alpha in human endometrium, decidua, and trophoblast
43. Localization of interleukin type 1 receptor and interleukin-1 b in human endometrium throughout the menstrual cycle
44. Effects of interferon-gamma on secretion of vascular endothelial growth factor by endometrial stromal cells
45. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis
46. Comparison of VEGF, VEGF-B, VEGF-C, and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
47. Endometrial microvascular growth in normal and dysfunctional states
48. Expression of mRNA for vascular endothelial growth factor transmembraneous receptors Flt 1 and KDR, and the soluble receptor sflt in cycling human endometrium
49. Expression of vascular endothelial growth factor receptors in the human endometrium: Modulation during the menstrual cycle
50. Progesterone withdrawal up-regulates vascular endothelial growth factor receptor type 2 in the superficial zone stroma of the human and macaque endometrium: Potential relevance to menstruation
51. Protein, nucleotide inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
52. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
53. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastatis, and mortality rate
54. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids
55. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation